Press Release
Study Finds SureFlex® Steerable Guiding Sheath has Greater Contact Force Stability for Radiofrequency Ablations
January 23, 2020
TORONTO, JANUARY 23 – A study has found that use of Baylis Medical’s SureFlex Steerable Guiding Sheath results in greater contact force stability for radiofrequency ablations in pulmonary vein isolations. Stable contact force has been linked to more effective ablations, a therapy in which radiofrequency energy is used to create a lesion in cardiac tissue to restore proper heart rhythm.
The retrospective study, entitled Choice of Steerable Sheath Impacts Contact Force Stability During Pulmonary Vein Isolation, was conducted by Drs. Dipak Shah, Cardiologist, and Evan Hiner, Cardiology Fellow, at Ascension Providence Hospital. It was presented at the AF Symposium 2020 poster presentation on January 23.
“Consistent contact force from a steerable sheath is essential to delivering effective ablations,” said Dr. Shah. “In evaluating the contact force of two commonly used steerable sheaths, the SureFlex Steerable Guiding Sheath and the Agilis™ NxT Steerable Introducer, we found a higher ratio of efficient ablation lesions suggested by a greater stability in contact force with the SureFlex sheath.”
The SureFlex sheath was engineered to provide reliable performance through superior curve retention and consistent sheath tip contact force. The device also features an advanced sheath-to-dilator design for controlled crossing of the septum, and intuitive and high-precision steering.
“When designing the SureFlex sheath, we worked to understand and address the needs and pain points of physicians in regard to steerable sheaths. We are pleased to see the results of this study demonstrate the SureFlex sheath’s ability to deliver reliable procedural performance,” said Robert Harrison, Director of Research & Development, Cardiology at Baylis Medical.
About Baylis Medical
Baylis Medical is a leader in the development and commercialization of innovative medical devices in the field of cardiology, with a focus on left-heart access. Headquartered in Canada, and with offices world-wide, our clinical solutions have been Improving the Lives of People Around the World for over 30 years. For more information, visit www.baylismedical.com and connect with us on Twitter, LinkedIn and Instagram.
PRM-00549 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2020. SureFlex and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries. Other trademarks are property of their respective owners. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.
The retrospective study, entitled Choice of Steerable Sheath Impacts Contact Force Stability During Pulmonary Vein Isolation, was conducted by Drs. Dipak Shah, Cardiologist, and Evan Hiner, Cardiology Fellow, at Ascension Providence Hospital. It was presented at the AF Symposium 2020 poster presentation on January 23.
“Consistent contact force from a steerable sheath is essential to delivering effective ablations,” said Dr. Shah. “In evaluating the contact force of two commonly used steerable sheaths, the SureFlex Steerable Guiding Sheath and the Agilis™ NxT Steerable Introducer, we found a higher ratio of efficient ablation lesions suggested by a greater stability in contact force with the SureFlex sheath.”
The SureFlex sheath was engineered to provide reliable performance through superior curve retention and consistent sheath tip contact force. The device also features an advanced sheath-to-dilator design for controlled crossing of the septum, and intuitive and high-precision steering.
“When designing the SureFlex sheath, we worked to understand and address the needs and pain points of physicians in regard to steerable sheaths. We are pleased to see the results of this study demonstrate the SureFlex sheath’s ability to deliver reliable procedural performance,” said Robert Harrison, Director of Research & Development, Cardiology at Baylis Medical.
About Baylis Medical
Baylis Medical is a leader in the development and commercialization of innovative medical devices in the field of cardiology, with a focus on left-heart access. Headquartered in Canada, and with offices world-wide, our clinical solutions have been Improving the Lives of People Around the World for over 30 years. For more information, visit www.baylismedical.com and connect with us on Twitter, LinkedIn and Instagram.
PRM-00549 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2020. SureFlex and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries. Other trademarks are property of their respective owners. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.
Media Contact
media@baylismedical.com